1. H o n o r a r y M e m b e r s h i p
Prof. Dr. Karim Fizazi

2. MEDICAL AND SCIENTIFIC QUALIFICATIONS
H o n o r a r y M e m b e r s h i p
MEDICAL AND SCIENTIFIC QUALIFICATIONS
 1984 to 1990: Medical school, University of Poitiers, France
1995 : MD (Medical Oncology)
1997 : « Ancien Chef de Clinique » Fellowship, Medical Oncology
2003: Ph.D. Molecular Oncology:
 “Development and use of preclinical models for the study of biology and
treatment of metastases from prostate cancer”   

3. MEDICAL ONCOLOGY CAREER
H o n o r a r y M e m b e r s h i p
MEDICAL ONCOLOGY CAREER
: Assistant Professor in Medical Oncology, department of Medicine, IGR
: Visiting Assistant Professor, Genitourinary Medical Oncology Department, MD Anderson cancer Center, Houston, TX, USA
2001. Assistant Professor in Medical Oncology, Department of Medicine, IGR
2004. Chairman of the Genito-urinary Oncology Group, IGR
2005. Appointed Head of the Department of Medicine, IGR
2009. Full Professor, Institut Gustave Roussy, University of Paris, France   

4. H o n o r a r y M e m b e r s h i p
EDITORIAL ACTIVITIES
Editorial board member of Journal of Clinical Oncology ( )
Associate Editor of Annals of Oncology ( )
Consulting Editor of European Urology since 2012
Associate editor of European Journal of Cancer (since 2014)
Ad hoc reviewer:
Annals of Oncology, Journal of Clinical Oncology, Clinical Cancer Research,
European Journal of Cancer, British Journal of Cancer, Drugs, European Urology
 Bulletin du Cancer Reviewer for “Health and Quality of Life” Editorial Office 
Reviewer “ New England Journal of Medicine” and “Lancet Oncology”

5. SCIENTIFIC SOCIETIES AND COLLABORATIONS
H o n o r a r y M e m b e r s h i p
SCIENTIFIC SOCIETIES AND COLLABORATIONS
President of the French Study Group of Carcinomas of Unknown Primary (GEFCAPI) since 1997
Member and investigator of the Uro-genital Tumors Study Group (GETUG)  since 1996
Member of the European Association of Urology: Testicular Cancer Panel (2011)
Member of the American Society of Medical Oncology (ASCO)
Member of the European Society of Medical Oncology (ESMO)
Member of the American Association for Cancer Research (AACR)

6. CURRENT MAIN ACTIVITIES IN CLINICAL RESEARCH
H o n o r a r y M e m b e r s h i p
CURRENT MAIN ACTIVITIES IN CLINICAL RESEARCH
Principal investigator of the phase III LATITUDE trial of Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Principal investigator of the phase III Enthuse 33 trial of docetaxel with or without ZD 4054 in metastatic castration resistant prostate cancer
Principal investigator of the phase III trial (103 trial) of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer
Principal Investigator of the French-American phase III trial in poor-prognosis non seminomatous germ-cell tumors (GETUG 13 trial)
Principal Investigator of the National French phase III trial of hormone therapy with and without docetaxel-estramustine in locally-advanced prostate cancer (GETUG 12 trial)
Principal Investigator of the National French phase III trial of cisplatin with and without gemcitabine in good prognosis carcinomas of unknown primaries (GEFCAPI 02 trial)
Principal Investigator of the « International validation study of patients with advanced non-seminomatous germ-cell tumors (NSGCT) and viable malignant cells at resection of residual masses » (12 European and American participating centers)

7. CURENT MAIN ACTIVITIES IN CLINICAL RESEARCH
H o n o r a r y M e m b e r s h i p
CURENT MAIN ACTIVITIES IN CLINICAL RESEARCH
Principal Investigator of the French multicenter Phase II study of gemcitabine, cisplatin, ifosfamide in patients with relapsing germ-cell tumors
Principal Investigator of the docetaxel-samarium Phase II study in castration resistant prostate cancer
Principal Investigator of the bicalutamide with or without ZD 6474 randomized Phase II study in castration-resistant prostate cancer
Principal Investigator of the French multicenter study of cisplatin, etoposide with or without ifosfamide in patients with metastatic seminoma
Principal Investigator of the phase II trial assessing PET-FDG in stage I seminoma
European Principal Investigator of the mitoxantrone with or without CNTO 328 randomized Phase II study in castration-resistant prostate cancer pretreated with docetaxel
European Principal Investigator of the phase III trial testing docetaxel with or without lenalidomide in metastatic castration-resistant prostate cancer

8. H o n o r a r y M e m b e r s h i p
"Welcome Karim.
Congratulations for your MKOT Honorary Membership and thank you for your extraordinary contribution and achievements to prostate cancer hormontherapy.”
Best regards,
Aimery
Aimery de Gramont

9. Karim Fizazi is an outstanding oncologist who has made a
H o n o r a r y M e m b e r s h i p
Karim Fizazi is an outstanding oncologist who has made a
remarkable contribution to the  management of  urological cancers.
He has an international standing in the field, and is a thoroughly
decent human being.
David J Kerr

10. H o n o r a r y M e m b e r s h i p
It's good that you are honouring Karim in this way - he has led several practice-changing trials for prostate cancer and contributed to many more. 
However he's not the sort of person that brings to mind humorous anecdotes - I've never seen him flustered or in any amusing situation.  He's always polite, modest  and reserved, never one to push himself forward.
Ian Tannock

11. „Fantastic, focused, dedicated clinical scientist as well as
H o n o r a r y M e m b e r s h i p
„Fantastic, focused, dedicated clinical scientist as well as
excellent and compassionate clinician.”
Alberto Sobrero

12. Honorary members (HSCO)
H o n o r a r y M e m b e r s h i p
Honorary members (HSCO)
Prof. Dr. Heine Hansen (2002)
Prof. Dr. Jan B. Vermorken (2004)
Prof. Dr. Richard Herrmann (2006)
Prof. Dr. Hans-Joachim Schmoll (2008)
Prof. Dr. Aimery de Gramont (2010)
Prof. dr. Tabár László (2012)
Prof dr. Alberto Sobrero (2014)
Prof dr. David J. Kerr (2016)
Prof. dr. Karim Fizazi (2018)

13. H o n o r a r y M e m b e r s h i p

14. H o n o r a r y M e m b e r s h i p